ASICS Study Shows Exercise Has the Power to Sharpen Even the Brightest Minds and Improve Mental Performance
20.1.2023 12:23:00 EET | Business Wire | Press release
Today, ASICS reveals exercise can significantly improve cognitive function and advance mental performance. From boosting short-term memory to increasing concentration levels, exercise enhances brain power and could be the solution to helping us pass exams or excel at work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230119005693/en/
Memory sport competitor, Ben Pridmore took part in the ASICS Mind Games study (Photo: Business Wire)
In a unique experiment, ASICS invited competitive gamers from around the world, specialising in mind games such as Chess and Esports and who rely on their cognitive function, to start an exercise programme. After four months of regular exercise, their minds were significantly sharpened and they performed at an even higher competitive level.
Participants’ international gaming rankings improved by an incredible 75% proving, yet again, the close interplay between our mind and body. The mind gamers’ cognitive function was boosted on average by 10%, with problem solving abilities improving by 9%, short-term memory increasing by 12% and processing speed and alertness improving by 10%. Group confidence levels increased by 44%, concentration improved by 33% and anxiety levels plummeted by 43%. The research shows exercise can be as effective at boosting brain function as learning a second language, daily reading, playing a new musical instrument or completing a puzzle every day.i
Professor Brendon Stubbs, a renowned researcher in movement and the mind, developed and led the experiment. Each gamer followed a training programme designed by runner turned international coach, Andrew Kastor. The programme included medium impact cardio and strength training and increased the gamers exercise levels to 150 minutes a week. Professor Stubbs measured the mental improvement of the participants based on their performance in their mind games, cognitive tests and wellbeing questionnaires over the course of their four-month research period.
Commenting on the results, Professor Brendon Stubbs said: “We all know that exercise is good for our mental and physical health but the impact on cognitive functioning has been less explored. We wanted to examine the effects of exercise on people who depend on their cognitive abilities - competitive mind gamers. Our results show significant improvements in their cognitive functioning, including concentration levels and problem-solving abilities.
“Exercise stimulates cell growth in the brain and rapidly increases blood flow to the hippocampus and prefrontal cortex, mechanisms that enable us to better retain memories, process information and problem solve quickly. If exercise can significantly increase the mental performance of professional mind gamers, imagine what it could do for the rest of us. From increasing focus when revising for an exam or improving alertness before a work presentation, exercise truly can enhance brain power.”
As well as showing that exercise improved the participants cognitive function and gaming capabilities, Professor Stubbs also found that the gamers’ mental wellbeing was significantly uplifted, with average State of Mind scores improving by 31%.ii The gamers’ average state of mind score at the start of the study was a below average 58 and at the end it was a high 76iii, demonstrating the significant impact exercise can also have on your mental wellbeing.
The study’s Head Coach, Andrew Kastor, who developed the gamers’ training programmes, stated: “These results are astonishing and speak to the power of exercise. Many of the gamers couldn’t jog for longer than a minute at the start of the study, so their training programmes had to be moderate. 150 minutes a week sounds a lot but when you break it down this could be 5 sets of 30 minutes. No matter your fitness levels, the mental benefits of exercise are accessible to all.”
Inspired by the experiment, a camera crew followed four competitive gamers as they took on regular exercise to improve their rankings on the international stage. The result was a new ground-breaking documentary ‘Mind Games – The Experiment’, narrated by the internationally acclaimed actor, and mental health campaigner, Stephen Fry. Now available to stream on Prime Video, the feature length film documents the journeys of four gamers – Kassa Korley, Ryoei Hirano, Ben Pridmore and Sherry Nhan – who specialise in Chess, Mahjong, Memory and Esports as they compete in professional tournaments around the world. Watch the documentary trailer here.
Gary Raucher, EVP, ASICS EMEA said: “Our founding philosophy is literally in our name, Anima Sana In Corpore Sano or a Sound Mind in a Sound Body. We have always encouraged utilising exercise for both physical and mental benefits, but this is the first time we have explored the true impact on cognitive functioning. Mind Games – The Experiment shows the power of exercise to sharpen the mind and we hope that after watching the documentary, everyone (regardless of their age, body type or fitness level) is inspired to move to help boost their brain.”
Mind Games - The Experiment is available to stream on Prime Video from 19th January 2023.
ENDS
Notes to Editors
The ASICS study ran from May – September 2022, with 77 gamers from 20 countries completing the experiment. All passed health screening questionnaires and completed consent forms before taking part.
For further information, images or to organise an interview with Professor Brendon Stubbs, Head Coach Andrew Kastor, or one of the gamers featured in the documentary, please contact Rory Cramsie at ASICSMindGames@golin.com
i Comparisons drawn from: https://journals.sagepub.com/doi/full/10.1177/09567976221092726 and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174231/ and https://www.frontiersin.org/articles/10.3389/fnagi.2021.706672/full#:~:text=Bilingualism%20has%20been%20linked%20to,cognitive%20enhancement%20in%20older%20adults
ii ASICS proprietary State of Mind score is a rating out of 100 made up of 10 emotional and cognitive metrics, including: composure, resilience, positivity, contentment, relaxation, confidence, alertness, calmness, focus and energy.
iii After four months the groups state of mind score increased into the top 10% globally.
Anima Sana In Corpore Sano, meaning “A Sound Mind in a Sound Body,” is an old Latin phrase from which ASICS is derived and the fundamental platform on which the brand still stands. The company was founded in 1949 by Kihachiro Onitsuka and is now a leading designer, developer and manufacturer of running shoes, as well as various sports footwear, apparel and accessories. For more information, visit www.asics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005693/en/
Contact information
Rory Cramsie
ASICSMindGames@golin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
